Tempus AI - Precision Medicine

Tempus AI has emerged as the dominant force in AI-powered precision medicine, reporting $1.3 billion in revenue for 2025, an 83.4% year-over-year increase that places it among the fastest-growing healthcare technology companies in the world. The company's diagnostics segment was the primary growth engine, generating $955.4 million in revenue with a staggering 111.5% year-over-year increase. Founded by Eric Lefkofsky, Tempus has built the largest library of clinical and molecular data in the healthcare industry, combining genomic sequencing, clinical records, imaging data, and real-world outcomes to power AI models that help clinicians make more informed treatment decisions.

The $81.25 million acquisition of Paige AI in 2025 significantly expanded Tempus's capabilities in computational pathology. Paige brought with it a dataset of more than 7 million digitized pathology slides, along with FDA-cleared algorithms for cancer detection in tissue samples. This acquisition positions Tempus to integrate molecular diagnostics with AI-driven pathology analysis, creating a more comprehensive diagnostic platform than any competitor currently offers. The combination of genomic data and pathology imaging enables multimodal AI models that can identify patterns invisible to any single data modality, potentially improving both diagnostic accuracy and treatment selection.

Tempus's FDA approval for its prostate cancer detection algorithm represents another critical milestone. Prostate cancer is the most commonly diagnosed cancer among men in the United States, with approximately 300,000 new cases annually. Current diagnostic pathways rely heavily on biopsy interpretation by pathologists, a process subject to significant inter-observer variability. Tempus's AI algorithm standardizes the grading process, reducing variability and flagging cases that require additional clinical attention. The FDA clearance validates the algorithm's safety and efficacy for clinical use, opening the door to widespread adoption across urology practices and hospital systems.

What distinguishes Tempus from other precision medicine companies is its data network effects. Every patient whose data flows through the Tempus platform makes the AI models more accurate for future patients. With partnerships spanning major cancer centers, community oncology practices, and pharmaceutical companies, Tempus has created a flywheel in which clinical volume drives data acquisition, which improves model performance, which attracts more clinical partners. This virtuous cycle is extremely difficult for competitors to replicate, as it requires both the technology infrastructure to process multimodal health data at scale and the clinical relationships necessary to access that data in the first place.

For the healthcare industry, Tempus's rapid growth validates the thesis that AI-powered precision medicine is transitioning from research concept to clinical standard of care. Oncologists, pathologists, and other specialists are increasingly relying on AI-driven insights to guide treatment decisions, particularly in complex cases where multiple therapeutic options exist. As Tempus expands beyond oncology into cardiology, neuropsychiatry, and infectious disease, the platform's ability to integrate diverse data types and deliver actionable clinical intelligence positions it to reshape how medicine is practiced across virtually every specialty.